文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

尼塞韦单抗预防婴儿首个呼吸道合胞病毒流行季相关住院效果的早期估计——新疫苗监测网络,2023年10月至2024年2月

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-03-07

新疫苗监测网络评估了2023年10月1日至2024年2月29日期间尼塞韦单抗对婴儿首个呼吸道合胞病毒(RSV)流行季相关住院的效果。在699名因急性呼吸道疾病住院的婴儿中,59名(8%)在症状出现前≥7天接受了尼塞韦单抗;尼塞韦单抗对RSV相关住院的有效性为90%(95% CI=75%-96%),从接种到症状出现的中位时间为45天(IQR=19-76天)。尽管接种率和接种间隔有限,这一早期估计支持当前尼塞韦单抗推荐。

要点

  • 尼塞韦单抗对婴儿首个RSV流行季相关住院的有效性为90%(95% CI=75%-96%)。
  • 接种到症状出现的中位时间为45天(IQR=19-76天)。
  • 接种婴儿数太少,无法按接种后时间分层;抗体衰减预期有效性随时间下降。

核心结论

  • 尽管本分析中尼塞韦单抗接种率和接种间隔有限,这一早期估计支持当前尼塞韦单抗用于预防婴儿严重RSV疾病的推荐。
  • 婴儿应通过母亲RSV疫苗接种或婴儿接受尼塞韦单抗获得保护。

研究设计与样本

  • 新疫苗监测网络评估尼塞韦单抗对婴儿首个RSV流行季相关住院的有效性,分析时段为2023年10月1日至2024年2月29日。
  • 分析纳入699名因急性呼吸道疾病住院的婴儿。

主要发现

  • 699名因急性呼吸道疾病住院的婴儿中,59名(8%)在症状出现前≥7天接受了尼塞韦单抗。
  • 尼塞韦单抗对RSV相关住院的有效性为90%(95% CI=75%-96%),从接种到症状出现的中位时间为45天(IQR=19-76天)。
  • 接受尼塞韦单抗的婴儿数太少,无法按接种后时间分层;但由于抗体衰减,尼塞韦单抗有效性预期随接种后时间增加而下降。

关键数值与推荐

  • 2023年8月,CDC免疫实践咨询委员会推荐尼塞韦单抗(一种长效单克隆抗体)用于年龄<8月龄的婴儿,以在首个RSV流行季预防RSV相关下呼吸道感染。
  • CDC免疫实践咨询委员会还推荐尼塞韦单抗用于年龄8-19月龄且严重RSV疾病风险增加的儿童。
  • 3期临床试验中,尼塞韦单抗对RSV相关下呼吸道感染伴住院的有效性在接种后150天内为81%(95% CI=62%-90%)。

临床怎么用

  • 婴儿应通过母亲RSV疫苗接种或婴儿接受尼塞韦单抗获得保护。
  • 本早期估计支持当前尼塞韦单抗用于预防婴儿严重RSV疾病的推荐。

局限性

  • 本分析中接受尼塞韦单抗的婴儿数太少,无法按接种后时间分层。
  • 由于抗体衰减,尼塞韦单抗有效性预期随接种后时间增加而下降。
  • 本分析中尼塞韦单抗接种率和接种间隔有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infection with hospitalization was 81% (95% CI = 62%-90%) through 150 days after receipt; post-introduction effectiveness has not been assessed in the United States. In this analysis, the New Vaccine Surveillance Network evaluated nirsevimab effectiveness against RSV-associated hospitalization among infants in their first RSV season during October 1, 2023-February 29, 2024. Among 699 infants hospitalized with acute respiratory illness, 59 (8%) received nirsevimab ≥7 days before symptom onset. Nirsevimab effectiveness was 90% (95% CI = 75%-96%) against RSV-associated hospitalization with a median time from receipt to symptom onset of 45 days (IQR = 19-76 days). The number of infants who received nirsevimab was too low to stratify by duration from receipt; however, nirsevimab effectiveness is expected to decrease with increasing time after receipt because of antibody decay. Although nirsevimab uptake and the interval from receipt of nirsevimab were limited in this analysis, this early estimate supports the current nirsevimab recommendation for the prevention of severe RSV disease in infants. Infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Moline HL, Tannis A, Toepfer AP, et al. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38457312. doi:10.15585/mmwr.mm7309a4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。